News and Events

News

National Hemophilia Foundation Applauds First von Willebrand Disease Clinical Practice Guidelines Issued by NHLBI
May 6, 2008
Read Press Release

Humate-P^® Package Notification
Wednesday, July 25, 2007
Read Press Release

Humate-P^® Approved to Prevent Excessive Bleeding in VWD Patients
Undergoing Surgery
Monday, April 30, 2007
Read Press Release
Updated Prescribing Information

CSL Behring Announces Availability of Humate-P^® with Smaller Diluent
February 15, 2006
Read Press Release

Events

National Hemophilia Foundation
Annual Meeting
November 13-15, 2008
Denver, Colorado
www.hemophilia.org

The American Society of Hematology
50th Annual Meeting and Exposition
December 6-9, 2008
Moscone Convention Center
San Francisco, CA
www.hematology.org

^*Upcoming conference dates will be posted when they become available.

Most local hemophilia chapters have a Web site, which typically includes a calendar of events. To find a chapter near you, go to the National Hemophilia Foundation Web site at: www.hemophilia.org/chapters

Important Safety Information

Antihemophilic Factor/von Willebrand Factor Complex (Human), Dried, Pasteurized, Humate-P^® is indicated in adult patients for treatment and prevention of bleeding in hemophilia A (classical hemophilia). Humate-P^® is also indicated in adult and pediatric patients with von Willebrand disease (VWD) for (1) treatment of spontaneous and trauma-induced bleeding episodes, and (2) prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD, and patients with mild and moderate VWD for whom use of desmopressin is known or suspected to be inadequate.

Humate-P^® is contraindicated in individuals with a history of anaphylactic or severe systemic response to antihemophilic factor or von Willebrand factor preparations or to any of its components.

Thromboembolic events have been reported in VWD patients receiving coagulation factor replacement, especially in the setting of known risk factors for thrombosis. Caution should be exercised and antithrombotic measures considered.

Humate-P^® is derived from human plasma. As with all plasma-derived products, the risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Although few adverse reactions have been reported the most common are allergic-anaphylactic reactions, including urticaria, chest tightness, rash, pruritus, edema, shock, chills and fever, and hypervolemia. For patients undergoing surgery, the most common adverse reactions are postoperative wound or injection-site bleeding.

Please see accompanying full prescribing information for Humate-P^®.